Health
Cancer Prevention
Female CEOs

Iovance Biotherapeutics

$9.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.10 (1.06%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell IOVA and other stocks, options, ETFs, and crypto commission-free!

About

Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. Read More The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Employees
88
Headquarters
San Carlos, California
Founded
2007
Market Cap
1.17B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.17M
High Today
$9.72
Low Today
$9.36
Open Price
$9.54
Volume
240.54K
52 Week High
$18.25
52 Week Low
$7.26

Collections

Health
Cancer Prevention
Female CEOs
Biotechnology
Medical
Therapy
Technology
2013 IPO

News

Simply Wall StMar 5

Read This Before Selling Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares

We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we’d be remiss not to mention that insider sales have been known to precede tough periods for a business. So before you buy or sell Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), you may well want to know whether insiders have been buying or selling. Do Insider Transactions Matter? It’s quite normal to see company insiders, such as board members, trading in company stock, fro...

116
Seeking AlphaFeb 27

Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q4 2018 Results - Earnings Call Transcript

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2018 Results Earnings Conference Call February 27, 2019 4:30 PM ET Company Participants Timothy Morris - CFO Maria Fardis - President & CEO Debora Barton - SVP, Clinical Science Conference Call Participants Mark Breidenbach - Oppenheimer Boris Peaker - Cohen George Zavoico - B. Riley FBR Operator Good afternoon, and welcome to the Iovance Biotherapeutics Fourth Quarter and Year End 2018 Financial Results Conference Call. All participants are in a list...

180

Earnings

-$0.36
-$0.33
-$0.30
-$0.27
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.